Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0027960 (
mole
)
21,279
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Human melanoma cells growth arrest irreversibly, lose tumorigenic potential and terminally differentiate after treatment with a combination of fibroblast interferon (IFN-beta) and the protein kinase C activator mezerein (MEZ). Applying subtraction hybridization to this model differentiation system permitted cloning of melanoma differentiation associated gene-7,
mda-7
. Expression of
mda-7
inversely correlates with melanoma development and progression, with elevated expression in normal melanocytes and
nevi
and increasingly reduced expression in radial growth phase, vertical growth phase and metastatic melanoma. When expressed by means of a replication incompetent adenovirus (Ad.
mda-7
) growth of melanoma, but not normal early passage or immortal human melanocytes, is dramatically suppressed and cells undergo programmed cell death (apoptosis). Infection of metastatic melanoma cells with Ad.
mda-7
results in an increase in cells in the G(2)/M phase of the cell cycle and changes in the ratio of pro-apoptotic (BAX, BAK) to anti-apoptotic (BCL-2, BCL-XL) proteins. Ad.
mda-7
infection results in a temporal increase in
mda-7
mRNA and intracellular
MDA-7
protein in most of the melanocyte/melanoma cell lines and secretion of
MDA-7
protein is readily detected following Ad.
mda-7
infection of both melanocytes and melanoma cells. The present studies document a differential response of melanocytes versus melanoma cells to ectopic expression of
mda-7
and support future applications of
mda-7
for the gene-based therapy of metastatic melanoma.
...
PMID:The cancer growth suppressing gene mda-7 induces apoptosis selectively in human melanoma cells. 1185 Jul 99
The melanoma differentiation associated gene-7 (mda-7) cDNA was isolated by virtue of being induced during melanoma differentiation. Initial gene transfer studies convincingly demonstrated potent antitumor effects of mda-7. Further studies showed that the mechanism of antitumor activity was due to induction of apoptosis. Most striking was the tumor-selective killing by mda-7 gene transfer--normal cells were unaffected by Adenoviral delivery of mda-7 (Ad-mda7). A variety of molecules implicated in apoptosis and intracellular signaling are regulated by Ad-mda7 transduction. Different apoptosis effector proteins are regulated in different tumor types, suggesting that Ad-mda7 may regulate various signaling pathways. mda-7 encodes a secreted protein,
MDA-7
, which has now been designated as IL-24, and is a novel member of the IL-10 cytokine family.
MDA-7
/IL-24 protein is actively secreted from cells after mda-7 gene transfer. In human peripheral blood mononuclear cells (PBMC), STAT3 activation by
MDA-7
/IL-24 is followed by elaboration of secondary Th1 cytokines, demonstrating that
MDA-7
/IL-24 is a pro-Th1 cytokine. Furthermore,
MDA-7
/IL-24 is antagonized by the prototypic Th2 cytokine IL-10.
MDA-7
/IL-24 protein is endogenously expressed in cultured NK and B-cells and is also expressed in dendritic cells in tissues.
MDA-7
/IL-24 protein is expressed in
nevi
and melanoma primary tumors, to varying degrees, but is rarely expressed in malignant melanoma or other human tumors evaluated. Indeed, loss of
MDA-7
/IL-24 protein expression correlates strongly with melanoma tumor invasion and disease progression. The "bystander" effects proposed for
MDA-7
/IL-24 protein include immune stimulation, antiangiogenesis and receptor-mediated cytotoxicity. Thus, mda-7 is a unique multifunctional cytokine in the IL-10 family and may have potent antitumor utility in a clinical setting.
...
PMID:MDA-7/IL-24 is a unique cytokine--tumor suppressor in the IL-10 family. 1512 Jun 50
Expression of melanoma differentiation associated gene-7 (mda-7) also known as
interleukin 24
(
IL-24
) decreases during melanoma cell differentiation and induces apoptosis in melanoma cells but not in melanocytes. Here we identify a novel splice variant of the cancer growth suppressor gene mda-7/
IL-24
(mda-7s) that is differentially expressed in RNA preparations from normal human melanocytes, transformed melanocytes,
nevi
, subcutaneous metastasis, lymph node metastasis, and melanoma cell lines. The 450 bp mda-7s mRNA encodes a protein of 63 residues with a molecular weight of 12 kDa. mda-7s lacks exons 3 and 5 of the full-length transcript and contains only 14 amino acids of homology to
MDA-7
located within the signal peptide region of the wild-type sequence. Despite minimal homology, MDA-7S coprecipitates full length
MDA-7
and reduces secretion of cotransfected
MDA-7
. mda-7 and mda-7s are coexpressed in all RNA preparations other than subcutaneous and lymph node metastasis where mda-7s expression is lacking. mda-7s expression is therefore linked to a non-metastatic phenotype.
...
PMID:Loss of novel mda-7 splice variant (mda-7s) expression is associated with metastatic melanoma. 1530
A potentially less toxic approach for cancer therapy comprises induction of tumor cells to lose growth potential irreversibly and terminally differentiate. Combining this scheme termed 'differentiation therapy of cancer' with subtraction hybridization to human melanoma cells resulted in the cloning of melanoma differentiation associated (mda) genes displaying elevated expression as a consequence of induction of terminal differentiation. One originally novel gene,
mda-7
, was found to display elevated expression in normal melanocytes and
nevi
with progressive loss of expression as a consequence of melanoma development and progression to metastasis. Based on structure, biochemical properties and chromosomal location,
mda-7
has now been reclassified as interleukin (IL)-24, a member of the expanding IL-10 family of cytokines. In vitro cell culture and in vivo animal studies indicate that
mda-7
/IL-24 selectively induces programmed cell death (apoptosis) in multiple human cancers (including melanomas), without harming normal cells, and promotes profound anti-tumor activity in nude mice containing human tumor xenografts. Based on these remarkable properties, a Phase I clinical trial was conducted to test the safety of administration of
mda-7
/IL-24 by a replication incompetent adenovirus (Ad.
mda-7
; INGN 241) in patients with advanced solid cancers including melanoma.
mda-7
/IL-24 was found to be safe and to promote significant clinical activity, particularly in the context of patients with metastatic melanoma. These results provide an impetus for further clinical studies and document a central paradigm of cancer therapy, namely translation of basic science from the "bench to the bedside."
...
PMID:Melanoma differentiation associated gene-7/interleukin-24 (mda-7/IL-24): novel gene therapeutic for metastatic melanoma. 1720 63